Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 plus Adjuvant Temozolomide in Newly Diagnosed Glioblastoma
NCT04065087Phase 2Withdrawn
- Sponsor
- Genexine
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efineptakin alfa in glioblastoma (GBM), sponsored by Genexine. Planned start Aug 2019; status: withdrawn.
02
Drugs
efineptakin alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04065087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065087.